Inducing Apolipoprotein A-I Synthesis to Reduce Cardiovascular Risk: from ASSERT to SUSTAIN and Beyond

Overview

Journal Arch Med Sci

Specialty General Medicine

Date 2016 Dec 2

PMID 27904522

Citations 6

Authors

Belinda A Di Bartolo

Daniel J Scherer

Stephen J Nicholls

Affiliations

Soon will be listed here.

Abstract

Increasing attention has focused on efforts to promote the biological activities of high-density lipoproteins (HDL) in order to reduce cardiovascular risk. Targeting apolipoprotein A-I (apoA-I), the major protein carried on HDL particles, represents an attractive approach to promoting HDL by virtue of its ability to increase endogenous synthesis of functional HDL particles. A number of pharmacological strategies that target apoA-I, including upregulation of its production with the bromodomain and extraterminal (BET) protein inhibitor RVX-208, development of short peptide sequences that mimic its action, and administration as a component of reconstituted HDL particles, have undergone clinical development. The impact of these approaches on cardiovascular biomarkers will be reviewed.

Citing Articles

High-density lipoprotein cholesterol: how studying the 'good cholesterol' could improve cardiovascular health.

Diaz L, Bielczyk-Maczynska E Open Biol. 2025; 15(2):240372.

PMID: 39965658 PMC: 11835495. DOI: 10.1098/rsob.240372.

Highlighting Residual Atherosclerotic Cardiovascular Disease Risk.

Matsuura Y, Kanter J, Bornfeldt K Arterioscler Thromb Vasc Biol. 2018; 39(1):e1-e9.

PMID: 30586334 PMC: 6310032. DOI: 10.1161/ATVBAHA.118.311999.

Lack of Correlation of Plasma HDL With Fecal Cholesterol and Plasma Cholesterol Efflux Capacity Suggests Importance of HDL Functionality in Attenuation of Atherosclerosis.

Srivastava N, Cefalu A, Averna M, Srivastava R Front Physiol. 2018; 9:1222.

PMID: 30271349 PMC: 6142045. DOI: 10.3389/fphys.2018.01222.

Benefit of Apabetalone on Plasma Proteins in Renal Disease.

Wasiak S, Tsujikawa L, Halliday C, Stotz S, Gilham D, Jahagirdar R Kidney Int Rep. 2018; 3(3):711-721.

PMID: 29854980 PMC: 5976837. DOI: 10.1016/j.ekir.2017.12.001.

Hypercholesterolaemia - practical information for non-specialists.

Soran H, Adam S, Mohammad J, Ho J, Schofield J, Kwok S Arch Med Sci. 2018; 14(1):1-21.

PMID: 29379528 PMC: 5778427. DOI: 10.5114/aoms.2018.72238.

References

Shepherd J, Cobbe S, Ford I, Isles C, LORIMER A, Macfarlane P . Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995; 333(20):1301-7. DOI: 10.1056/NEJM199511163332001. View

Barylski M, Toth P, Nikolic D, Banach M, Rizzo M, Montalto G . Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality. Best Pract Res Clin Endocrinol Metab. 2014; 28(3):453-61. DOI: 10.1016/j.beem.2013.11.001. View

Angelin B, Parini P, Eriksson M . Reverse cholesterol transport in man: promotion of fecal steroid excretion by infusion of reconstituted HDL. Atheroscler Suppl. 2003; 3(4):23-30. DOI: 10.1016/s1567-5688(02)00047-8. View

Kraus W, Houmard J, Duscha B, Knetzger K, Wharton M, McCartney J . Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med. 2002; 347(19):1483-92. DOI: 10.1056/NEJMoa020194. View

Gordon D, Rifkind B . High-density lipoprotein--the clinical implications of recent studies. N Engl J Med. 1989; 321(19):1311-6. DOI: 10.1056/NEJM198911093211907. View

McEneny J, Blair S, Woodside J, Murray L, Boreham C, Young I . High-density lipoprotein subfractions display proatherogenic properties in overweight and obese children. Pediatr Res. 2013; 74(3):279-83. DOI: 10.1038/pr.2013.93. View

Taylor A, Sullenberger L, Lee H, Lee J, Grace K . Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with.... Circulation. 2004; 110(23):3512-7. DOI: 10.1161/01.CIR.0000148955.19792.8D. View

Boden W, Probstfield J, Anderson T, Chaitman B, Desvignes-Nickens P, Koprowicz K . Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011; 365(24):2255-67. DOI: 10.1056/NEJMoa1107579. View

Asztalos B, Collins D, Horvath K, Bloomfield H, Robins S, Schaefer E . Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Metabolism. 2007; 57(1):77-83. PMC: 2194640. DOI: 10.1016/j.metabol.2007.08.009. View

10.

Cui Y, Watson D, Girman C, Shapiro D, Gotto A, Hiserote P . Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study). Am J Cardiol. 2009; 104(6):829-34. DOI: 10.1016/j.amjcard.2009.05.020. View

11.

Rohrer L, Ohnsorg P, Lehner M, Landolt F, Rinninger F, von Eckardstein A . High-density lipoprotein transport through aortic endothelial cells involves scavenger receptor BI and ATP-binding cassette transporter G1. Circ Res. 2009; 104(10):1142-50. DOI: 10.1161/CIRCRESAHA.108.190587. View

12.

Sacks F, Pfeffer M, Moye L, Rouleau J, Rutherford J, Cole T . The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996; 335(14):1001-9. DOI: 10.1056/NEJM199610033351401. View

13.

Shah P, Yano J, Reyes O, Chyu K, Kaul S, Bisgaier C . High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization. Circulation. 2001; 103(25):3047-50. DOI: 10.1161/hc2501.092494. View

14.

Otocka-Kmiecik A, Mikhailidis D, Nicholls S, Davidson M, Rysz J, Banach M . Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?. Prog Lipid Res. 2012; 51(4):314-24. DOI: 10.1016/j.plipres.2012.03.003. View

15.

Nicholls S, Gordon A, Johannson J, Ballantyne C, Barter P, Brewer H . ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies. Cardiovasc Drugs Ther. 2012; 26(2):181-7. DOI: 10.1007/s10557-012-6373-5. View

16.

Kennedy D, Tang W, Fan Y, Wu Y, Mann S, Pepoy M . Diminished antioxidant activity of high-density lipoprotein-associated proteins in chronic kidney disease. J Am Heart Assoc. 2013; 2(2):e000104. PMC: 3647254. DOI: 10.1161/JAHA.112.000104. View

17.

Badimon J, Badimon L, Galvez A, DISCHE R, Fuster V . High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. Lab Invest. 1989; 60(3):455-61. View

18.

Spieker L, Sudano I, Hurlimann D, Lerch P, Lang M, Binggeli C . High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation. 2002; 105(12):1399-402. DOI: 10.1161/01.cir.0000013424.28206.8f. View

19.

Rohatgi A, Khera A, Berry J, Givens E, Ayers C, Wedin K . HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014; 371(25):2383-93. PMC: 4308988. DOI: 10.1056/NEJMoa1409065. View

20.

Angeloni E, Paneni F, Landmesser U, Benedetto U, Melina G, Luscher T . Lack of protective role of HDL-C in patients with coronary artery disease undergoing elective coronary artery bypass grafting. Eur Heart J. 2013; 34(46):3557-62. DOI: 10.1093/eurheartj/eht163. View